Rein Therapeutics Inc. (RNTX) Stock Price & Analysis
Rein Therapeutics Inc. (RNTX) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.3369 (-8.38%), as of the Nov 20, 2026 trading session; market cap $29.1M.
Educational signal · not a buy or sell recommendation · How to read this
Rein Therapeutics Inc. · RNTX · NASDAQ
Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for cancer and other diseases.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Rein Therapeutics (RNTX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, weak growth and an expensive valuation, though the balance sheet is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 4 reports
- Altman Z -7.75 · Piotroski F 2
Holding back: weak fundamentals, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.3369 | |
| Change on the day | -8.38% | |
| 52-week range | $0.3369 – $2.10 | |
| Market capitalisation | $29.1M | — |
| Shares traded on the day | 668.6K |
Price & events
Other perspectives
Council score for Rein Therapeutics (RNTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Rein Therapeutics (RNTX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Rein Therapeutics Inc. (RNTX) is listed on NASDAQ. It employs 10 people and is led by James Brian Windsor. The market values it at $29.1M.
What do the latest results show for Rein Therapeutics (RNTX)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $0 | -$6M | -$0.06 (diluted) |
| Q2 FY2026 | $0 | -$6M | -$0.21 (diluted) |
| Q1 FY2026 | $0 | -$6M | -$0.19 (diluted) |
| Q4 FY2025 | $0 | -$32M | -$1.26 (diluted) |
What are the financial strengths and risks for Rein Therapeutics (RNTX)?
Short answer
What is holding it back is weak fundamentals, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -7.75 · Piotroski F 2. Trailing ratios: ROA -24.6% · current ratio 6.57.
Data-derived red flags
- Listing risk — at $0.3369 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -7.75 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 4 reported quarters.
What should you watch next at Rein Therapeutics (RNTX)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Rein Therapeutics compare with its peers?
Short answer
Rein Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $166.53 Nov 19, 2026 | $207B | 72 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| $10.02 Nov 20, 2026 | $148M | 61 5-pillar Nov 18, 2026 | |
| Rein Therapeutics (RNTX) — this page | $0.3369 | $29.1M | 30 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 3, 2026)
- $6.00 – $6.00
- Last captured analyst target (expired, captured Nov 3, 2026)
- $6.00
- Last captured median analyst target (expired, captured Nov 3, 2026)
- $6.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated May 27, 2026
- Transactions
- 2
- Identified insiders
- 1
- Purchases
- 2
- Sales
- 0
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RNTX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RNTX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Rein Therapeutics (RNTX)?
- Rein Therapeutics Announces Preliminary Phase 2 RENEW Data and Q3 2026 Financial Results
- Rein reports early Phase II data for inhaled IPF drug
- Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results
Common Questions About RNTX
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for RNTX?
RNTX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is RNTX a good stock to buy?
Stock Expert AI does not rate RNTX buy, sell or hold. Rein Therapeutics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RNTX stock price today?
The last price recorded for Rein Therapeutics Inc. (RNTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RNTX price target?
The last analyst consensus price target we captured for Rein Therapeutics Inc. (RNTX), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What are the key factors to evaluate for RNTX?
Rein Therapeutics Inc. (RNTX) holds a MoonshotScore in the low range. The company does not currently offer a dividend, consistent with its focus on reinvesting in research and development. Not financial advice.
How frequently does RNTX data refresh on this page?
RNTX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RNTX's recent stock price performance?
Rein Therapeutics Inc. (RNTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RNTX overvalued or undervalued right now?
Rein Therapeutics Inc. (RNTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RNTX?
Fractional-share availability for Rein Therapeutics Inc. (RNTX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com